Article citationsMore>>
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S. and Kishimoto, T. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755-764.
http://dx.doi.org/10.1016/S0092-8674(00)80258-5
has been cited by the following article:
-
TITLE:
Prohibitins, novel vitamin K2 target factors in osteoblast
AUTHORS:
Tatsuya Uebi, Makoto Umeda, Naoya Maekawa, Satoshi Karasawa, Hiroshi Handa, Takeshi Imai
KEYWORDS:
Vitamin K2; Prohibitin; Osteoblast; Runt-Related Transcription Factor 2 (Runx2)
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.1 No.3,
December
12,
2013
ABSTRACT:
Vitamin K2 (VK2,
menaquinone) is a drug for osteoporosis.
VK2 acts as a cofactor for γ-glutamyl carboxylase, which catalyzes the
carboxylation of specific glutamic acid residues (γ-carboxylation)
of substrate proteins. Here we demonstrate that VK2 also regulate
osteoblastgenic marker gene expression. Using VK2-immobilzed nanobeads new target proteins
were purified and
identified from osteoblastic cell line. They are prohibitin 1 and 2 (PHB1 &
2), respectively. To confirm the PHBs function on VK2-dependent transcription, PHB1 & 2 were knock-down
and osteocalcin gene 2 transcriptions were analyzed, indicating that PHBs
regulate VK2-dependent transcription. Taken together PHBs are VK2 target
proteins for osteoblastgenic transcription.
Related Articles:
-
Laurence Stephenson
-
Mina Ghareeb Faraj, Nada Yassen Kasm
-
Indra Rajasingh, Bharati Rajan, Ramanathan Sundara Rajan
-
R. Douglas Martin, Shengyu Zhang
-
Valerii Ermakov, Volodymyr Kolomoets, Leonid Panasyuk, Baja Orasgulyev